{"id":79415,"date":"2026-09-08T12:48:18","date_gmt":"2026-09-08T04:48:18","guid":{"rendered":"https:\/\/flcube.com\/?p=79415"},"modified":"2026-09-08T12:48:19","modified_gmt":"2026-09-08T04:48:19","slug":"clinical-stage-biopharma-revelyx-bio-launches-with-exclusive-global-license-for-yy003-ready-to-use-recombinant-botulinum-toxin-type-a","status":"publish","type":"post","link":"https:\/\/flcube.com\/clinical-stage-biopharma-revelyx-bio-launches-with-exclusive-global-license-for-yy003-ready-to-use-recombinant-botulinum-toxin-type-a\/","title":{"rendered":"Clinical\u2011Stage Biopharma Revelyx Bio Launches with Exclusive Global License for YY003 \u2013 Ready\u2011to\u2011Use Recombinant Botulinum Toxin Type A"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Clinical\u2011stage biopharmaceutical company <strong>Revelyx Bio, Inc.<\/strong> announced on <strong>August 31, 2026<\/strong> its <strong>official launch<\/strong>, backed by an <strong>exclusive licensing agreement<\/strong> with <strong>Chongqing Claruvis Pharmaceutical Co., Ltd.<\/strong> for <strong>YY003<\/strong>, a <strong>ready\u2011to\u2011use liquid formulation of recombinant botulinum toxin type A (rBoNT\/A)<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-deal-structure\" class=\"wp-block-heading\">Deal Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensee \/ New Company<\/strong><\/td><td>Revelyx Bio, Inc. (clinical\u2011stage biopharmaceutical company)<\/td><\/tr><tr><td><strong>Licensor<\/strong><\/td><td>Chongqing Claruvis Pharmaceutical Co., Ltd.<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td><strong>YY003<\/strong> \u2014 ready\u2011to\u2011use liquid formulation of recombinant botulinum toxin type A (rBoNT\/A)<\/td><\/tr><tr><td><strong>Rights Granted<\/strong><\/td><td>Exclusive development and commercialization for <strong>aesthetic and therapeutic indications<\/strong><\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td><strong>Global, excluding mainland China, Hong Kong, and Macau<\/strong><\/td><\/tr><tr><td><strong>Launch Date<\/strong><\/td><td>31 Aug 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profile-amp-formulation\" class=\"wp-block-heading\">Product Profile &amp; Formulation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Presentation:<\/strong> Investigational rBoNT\/A formulated as a <strong>ready\u2011to\u2011use liquid<\/strong>, presented in a <strong>prefilled syringe<\/strong> \u2014 eliminating reconstitution steps required by conventional botulinum toxin products<\/li>\n\n\n\n<li><strong>Manufacturing Platform:<\/strong> Produced via <strong>recombinant expression in <em>E. coli<\/em><\/strong>, rather than traditional <strong><em>Clostridium botulinum<\/em> culture purification<\/strong><\/li>\n\n\n\n<li><strong>Quality Control:<\/strong> The recombinant process offers <strong>precise control over neurotoxin identity and purity<\/strong><\/li>\n\n\n\n<li><strong>Structural Fidelity:<\/strong> The resulting protein is <strong>structurally identical to naturally derived neurotoxin<\/strong>, offering the potential for <strong>high specific activity<\/strong> and an <strong>enhanced safety profile<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Botulinum Toxin Market Overhaul:<\/strong> The global botulinum toxin market \u2014 spanning aesthetics (wrinkle treatment) and therapeutics (spasticity, migraine, hyperhidrosis) \u2014 is dominated by products requiring reconstitution and derived from <em>Clostridium<\/em> culture. A ready\u2011to\u2011use prefilled syringe could improve dosing accuracy, workflow, and consistency in clinics.<\/li>\n\n\n\n<li><strong>Recombinant Differentiation:<\/strong> Manufacturing rBoNT\/A in <em>E. coli<\/em> removes dependence on pathogenic bacterial culture, addressing batch\u2011to\u2011batch variability and biosecurity concerns inherent to traditional production.<\/li>\n\n\n\n<li><strong>New Entrant, Established Asset:<\/strong> Revelyx Bio launches as a pure\u2011play company around a single differentiated asset, with worldwide ex\u2011Greater China rights covering both aesthetic and therapeutic indications.<\/li>\n\n\n\n<li><strong>Strategic Fit for Claruvis:<\/strong> The license retains Greater China rights for the licensor while monetizing international markets through Revelyx&#8217;s global development program.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development, regulatory approvals, and commercialization of YY003. Actual results may differ due to risks including trial outcomes, regulatory timelines, manufacturing scale\u2011up, market adoption, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Clinical\u2011stage biopharmaceutical company Revelyx Bio, Inc. announced on August 31, 2026 its official launch, backed&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[4939,100,4938],"class_list":["post-79415","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-claruvis-pharmaceutical","tag-medical-aesthetics","tag-revelyx-bio"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Clinical\u2011Stage Biopharma Revelyx Bio Launches with Exclusive Global License for YY003 \u2013 Ready\u2011to\u2011Use Recombinant Botulinum Toxin Type A - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Clinical\u2011stage biopharmaceutical company Revelyx Bio, Inc. announced on August 31, 2026 its official launch, backed by an exclusive licensing agreement with Chongqing Claruvis Pharmaceutical Co., Ltd. for YY003, a ready\u2011to\u2011use liquid formulation of recombinant botulinum toxin type A (rBoNT\/A).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/clinical-stage-biopharma-revelyx-bio-launches-with-exclusive-global-license-for-yy003-ready-to-use-recombinant-botulinum-toxin-type-a\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clinical\u2011Stage Biopharma Revelyx Bio Launches with Exclusive Global License for YY003 \u2013 Ready\u2011to\u2011Use Recombinant Botulinum Toxin Type A\" \/>\n<meta property=\"og:description\" content=\"Clinical\u2011stage biopharmaceutical company Revelyx Bio, Inc. announced on August 31, 2026 its official launch, backed by an exclusive licensing agreement with Chongqing Claruvis Pharmaceutical Co., Ltd. for YY003, a ready\u2011to\u2011use liquid formulation of recombinant botulinum toxin type A (rBoNT\/A).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/clinical-stage-biopharma-revelyx-bio-launches-with-exclusive-global-license-for-yy003-ready-to-use-recombinant-botulinum-toxin-type-a\/\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-08T04:48:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-08T04:48:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/clinical-stage-biopharma-revelyx-bio-launches-with-exclusive-global-license-for-yy003-ready-to-use-recombinant-botulinum-toxin-type-a\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/clinical-stage-biopharma-revelyx-bio-launches-with-exclusive-global-license-for-yy003-ready-to-use-recombinant-botulinum-toxin-type-a\\\/\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Clinical\u2011Stage Biopharma Revelyx Bio Launches with Exclusive Global License for YY003 \u2013 Ready\u2011to\u2011Use Recombinant Botulinum Toxin Type A\",\"datePublished\":\"2026-09-08T04:48:18+00:00\",\"dateModified\":\"2026-09-08T04:48:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/clinical-stage-biopharma-revelyx-bio-launches-with-exclusive-global-license-for-yy003-ready-to-use-recombinant-botulinum-toxin-type-a\\\/\"},\"wordCount\":369,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Claruvis Pharmaceutical\",\"Medical aesthetics\",\"Revelyx Bio\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/clinical-stage-biopharma-revelyx-bio-launches-with-exclusive-global-license-for-yy003-ready-to-use-recombinant-botulinum-toxin-type-a\\\/#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/clinical-stage-biopharma-revelyx-bio-launches-with-exclusive-global-license-for-yy003-ready-to-use-recombinant-botulinum-toxin-type-a\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/clinical-stage-biopharma-revelyx-bio-launches-with-exclusive-global-license-for-yy003-ready-to-use-recombinant-botulinum-toxin-type-a\\\/\",\"name\":\"Clinical\u2011Stage Biopharma Revelyx Bio Launches with Exclusive Global License for YY003 \u2013 Ready\u2011to\u2011Use Recombinant Botulinum Toxin Type A - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-09-08T04:48:18+00:00\",\"dateModified\":\"2026-09-08T04:48:19+00:00\",\"description\":\"Clinical\u2011stage biopharmaceutical company Revelyx Bio, Inc. announced on August 31, 2026 its official launch, backed by an exclusive licensing agreement with Chongqing Claruvis Pharmaceutical Co., Ltd. for YY003, a ready\u2011to\u2011use liquid formulation of recombinant botulinum toxin type A (rBoNT\\\/A).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/clinical-stage-biopharma-revelyx-bio-launches-with-exclusive-global-license-for-yy003-ready-to-use-recombinant-botulinum-toxin-type-a\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/clinical-stage-biopharma-revelyx-bio-launches-with-exclusive-global-license-for-yy003-ready-to-use-recombinant-botulinum-toxin-type-a\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/clinical-stage-biopharma-revelyx-bio-launches-with-exclusive-global-license-for-yy003-ready-to-use-recombinant-botulinum-toxin-type-a\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Clinical\u2011Stage Biopharma Revelyx Bio Launches with Exclusive Global License for YY003 \u2013 Ready\u2011to\u2011Use Recombinant Botulinum Toxin Type A\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/author\\\/wesley\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Clinical\u2011Stage Biopharma Revelyx Bio Launches with Exclusive Global License for YY003 \u2013 Ready\u2011to\u2011Use Recombinant Botulinum Toxin Type A - Insight, China&#039;s Pharmaceutical Industry","description":"Clinical\u2011stage biopharmaceutical company Revelyx Bio, Inc. announced on August 31, 2026 its official launch, backed by an exclusive licensing agreement with Chongqing Claruvis Pharmaceutical Co., Ltd. for YY003, a ready\u2011to\u2011use liquid formulation of recombinant botulinum toxin type A (rBoNT\/A).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/clinical-stage-biopharma-revelyx-bio-launches-with-exclusive-global-license-for-yy003-ready-to-use-recombinant-botulinum-toxin-type-a\/","og_locale":"en_US","og_type":"article","og_title":"Clinical\u2011Stage Biopharma Revelyx Bio Launches with Exclusive Global License for YY003 \u2013 Ready\u2011to\u2011Use Recombinant Botulinum Toxin Type A","og_description":"Clinical\u2011stage biopharmaceutical company Revelyx Bio, Inc. announced on August 31, 2026 its official launch, backed by an exclusive licensing agreement with Chongqing Claruvis Pharmaceutical Co., Ltd. for YY003, a ready\u2011to\u2011use liquid formulation of recombinant botulinum toxin type A (rBoNT\/A).","og_url":"https:\/\/flcube.com\/clinical-stage-biopharma-revelyx-bio-launches-with-exclusive-global-license-for-yy003-ready-to-use-recombinant-botulinum-toxin-type-a\/","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-09-08T04:48:18+00:00","article_modified_time":"2026-09-08T04:48:19+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/clinical-stage-biopharma-revelyx-bio-launches-with-exclusive-global-license-for-yy003-ready-to-use-recombinant-botulinum-toxin-type-a\/#article","isPartOf":{"@id":"https:\/\/flcube.com\/clinical-stage-biopharma-revelyx-bio-launches-with-exclusive-global-license-for-yy003-ready-to-use-recombinant-botulinum-toxin-type-a\/"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Clinical\u2011Stage Biopharma Revelyx Bio Launches with Exclusive Global License for YY003 \u2013 Ready\u2011to\u2011Use Recombinant Botulinum Toxin Type A","datePublished":"2026-09-08T04:48:18+00:00","dateModified":"2026-09-08T04:48:19+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/clinical-stage-biopharma-revelyx-bio-launches-with-exclusive-global-license-for-yy003-ready-to-use-recombinant-botulinum-toxin-type-a\/"},"wordCount":369,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Claruvis Pharmaceutical","Medical aesthetics","Revelyx Bio"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/clinical-stage-biopharma-revelyx-bio-launches-with-exclusive-global-license-for-yy003-ready-to-use-recombinant-botulinum-toxin-type-a\/#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/clinical-stage-biopharma-revelyx-bio-launches-with-exclusive-global-license-for-yy003-ready-to-use-recombinant-botulinum-toxin-type-a\/","url":"https:\/\/flcube.com\/clinical-stage-biopharma-revelyx-bio-launches-with-exclusive-global-license-for-yy003-ready-to-use-recombinant-botulinum-toxin-type-a\/","name":"Clinical\u2011Stage Biopharma Revelyx Bio Launches with Exclusive Global License for YY003 \u2013 Ready\u2011to\u2011Use Recombinant Botulinum Toxin Type A - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-09-08T04:48:18+00:00","dateModified":"2026-09-08T04:48:19+00:00","description":"Clinical\u2011stage biopharmaceutical company Revelyx Bio, Inc. announced on August 31, 2026 its official launch, backed by an exclusive licensing agreement with Chongqing Claruvis Pharmaceutical Co., Ltd. for YY003, a ready\u2011to\u2011use liquid formulation of recombinant botulinum toxin type A (rBoNT\/A).","breadcrumb":{"@id":"https:\/\/flcube.com\/clinical-stage-biopharma-revelyx-bio-launches-with-exclusive-global-license-for-yy003-ready-to-use-recombinant-botulinum-toxin-type-a\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/clinical-stage-biopharma-revelyx-bio-launches-with-exclusive-global-license-for-yy003-ready-to-use-recombinant-botulinum-toxin-type-a\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/clinical-stage-biopharma-revelyx-bio-launches-with-exclusive-global-license-for-yy003-ready-to-use-recombinant-botulinum-toxin-type-a\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Clinical\u2011Stage Biopharma Revelyx Bio Launches with Exclusive Global License for YY003 \u2013 Ready\u2011to\u2011Use Recombinant Botulinum Toxin Type A"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/author\/wesley\/"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/wp-json\/wp\/v2\/posts\/79415","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/wp-json\/wp\/v2\/comments?post=79415"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/wp-json\/wp\/v2\/posts\/79415\/revisions"}],"predecessor-version":[{"id":79417,"href":"https:\/\/flcube.com\/wp-json\/wp\/v2\/posts\/79415\/revisions\/79417"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/wp-json\/wp\/v2\/media?parent=79415"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/wp-json\/wp\/v2\/categories?post=79415"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/wp-json\/wp\/v2\/tags?post=79415"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}